Tacalyx

Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.

Health and bio

Tacalyx has no funding amount on record yet; its latest known round is Seed (Apr 2026). Recent Funding first saw it on October 2, 2026.

Founders and team

• PS
  Peter Seeberger Founder

  source: crunchbase.com
• PS
  Peter Sondermann Founder

  source: crunchbase.com

Raise history

1. April 29, 2026
   Seed · amount undisclosed
   Source: crunchbase.com

Related bio health companies

• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/tacalyx.